page_slug,page_title,parent_hub_name,parent_hub_url,hero_headline,hero_description,primary_content_title,primary_content_description,key_capabilities_title,capability_1_title,capability_1_description,capability_2_title,capability_2_description,capability_3_title,capability_3_description,capability_4_title,capability_4_description,capability_5_title,capability_5_description,capability_6_title,capability_6_description,why_choose_title,why_choose_1_icon,why_choose_1_title,why_choose_1_description,why_choose_2_icon,why_choose_2_title,why_choose_2_description,why_choose_3_icon,why_choose_3_title,why_choose_3_description,cta_title,cta_description,cta_primary_button_text,cta_primary_button_link
laa-closure-testing,LAA Closure Testing Services | GLP Preclinical CRO | Synchrony Labs,Structural Heart Testing,/preclinical-services/cardiovascular-disease-testing/structural-heart-testing,LAA Closure Testing Services,"Comprehensive preclinical testing for left atrial appendage closure devices with deployment accuracy, sealing effectiveness assessment, and anatomical compatibility validation across diverse appendage morphologies.",What We Test,"Left atrial appendage closure devices prevent stroke in atrial fibrillation patients by permanently sealing the appendage where blood clots form. These devices face unique validation challenges across diverse appendage anatomies, from chicken wing to cauliflower configurations, requiring precise deployment mechanics and complete sealing without peridevice leaks. Success depends on demonstrating anatomical compatibility across morphological variants, positioning accuracy during cardiac motion, and endothelialization that ensures permanent closure.

We evaluate deployment accuracy using transesophageal echocardiography and high-resolution fluoroscopy that capture device positioning throughout complete cardiac cycles. Our catheterization laboratories feature specialized left atrial access capabilities, anatomical models representing morphological variations, and flow measurement systems that quantify sealing effectiveness. From device-tissue interface characterization to chronic endothelialization assessment, our protocols address the specific performance requirements LAA closure technologies demand.

ISO 10993 biocompatibility standards guide chronic implantation studies while device specific protocols address deployment mechanics and anatomical compatibility validation. Our GLP compliant testing supports both 510(k) pathways demonstrating substantial equivalence to predicate devices and PMA submissions for breakthrough technologies. Whether validating nitinol framework designs or novel sealing mechanisms, our protocols address FDA expectations for stroke prevention devices across diverse patient anatomies.",Key Testing Capabilities,Anatomical Compatibility Assessment,"Deployment validation across chicken wing, cactus, cauliflower, and windsock LAA morphologies using anatomically accurate models with advanced imaging for detailed anatomical measurements and device sizing verification.",Deployment Mechanics and Positioning Accuracy,"High-resolution fluoroscopy and transesophageal echocardiography capture device deployment dynamics, positioning accuracy, and stability during cardiac motion with assessment of delivery system performance and retrieval capabilities.",Sealing Effectiveness and Leak Assessment,Advanced flow measurement techniques quantify LAA occlusion completeness and peridevice leak detection with real-time imaging during deployment enabling sealing optimization and long-term closure validation.,Endothelialization and Tissue Integration,"Extended observation protocols evaluate endothelialization progression and device-tissue interface healing with histopathological analysis characterizing tissue ingrowth, cellular responses, and complete endothelial coverage development.",Device Stability and Durability,Cardiac cycle simulation assesses device positioning stability and anchoring mechanism integrity throughout extended physiological loading with accelerated fatigue protocols characterizing material durability and long-term device behavior.,Biocompatibility and Thrombogenicity,ISO 10993-4 compliant hemocompatibility testing addresses blood contact requirements while specialized thrombogenicity protocols evaluate clot formation potential under atrial fibrillation flow patterns with chronic studies assessing tissue response over implant lifetime.,Why Choose Synchrony for LAA Closure Testing,Layers,Specialized Structural Heart Infrastructure,"Two catheterization laboratories equipped specifically for LAA closure evaluation feature transesophageal echocardiography, high-resolution fluoroscopy, and specialized left atrial access capabilities. Our anatomical model library spans chicken wing, cactus, cauliflower, and windsock morphologies while hemodynamic monitoring systems capture device-heart interactions throughout complete cardiac cycles.",Users,Structural Heart Device Expertise,"Founded by Duke University interventional cardiologists who pioneered transcatheter structural heart procedures, our team understands complex cardiac anatomy, deployment mechanics, and chronic tissue integration requirements. This cardiovascular heritage translates to protocol designs that address FDA Class III device requirements including anatomical compatibility demonstration, endothelialization assessment, and comprehensive safety validation.",Activity,Proven Structural Heart Regulatory Success,"Our data packages have supported successful FDA approvals for structural heart devices across LAA closure, septal defect, and transcatheter repair categories. We understand Class III device requirements including chronic biocompatibility demonstration through ISO 10993 compliance, deployment accuracy validation, and the specific endpoints FDA expects for structural heart device submissions.",Ready to Start Your Study?,"Our team is ready to discuss your LAA closure device, regulatory pathway, and study requirements to optimize your path to FDA approval.",Schedule Consultation,/contact
watchman-device-testing,Watchman Device Testing Services | GLP Preclinical CRO | Synchrony Labs,Structural Heart Testing,/preclinical-services/cardiovascular-disease-testing/structural-heart-testing,Watchman Device Testing Services,"Specialized preclinical validation for Watchman LAA occluders with nitinol framework characterization, fabric membrane assessment, and device stability testing across varying appendage anatomies.",What We Test,"Watchman devices represent the established standard for percutaneous LAA closure, requiring validation that addresses nitinol framework expansion, polyester fabric membrane sealing, and sizing accuracy across diverse appendage geometries. These self-expanding occluders must demonstrate controlled deployment, adequate wall apposition force, and complete appendage isolation while supporting endothelialization that prevents thrombus formation. Success depends on validating framework durability under cardiac loading, membrane integrity throughout device lifetime, and optimal sizing across the spectrum of LAA anatomical variations.

We evaluate framework performance using specialized expansion testing that quantifies radial force, shape memory recovery, and deployment consistency across temperature ranges. Our catheterization laboratories feature transesophageal echocardiography capabilities, anatomical models representing chicken wing through windsock morphologies, and flow measurement systems that assess sealing effectiveness. From nitinol fatigue characterization to fabric endothelialization studies, our protocols address the specific validation requirements Watchman platforms demand.

ISO 10993 biocompatibility standards guide nitinol and fabric material assessment while device specific protocols address compression ratio optimization and anchoring stability validation. Our GLP compliant testing supports both 510(k) pathways for devices demonstrating substantial equivalence to established Watchman predicates and PMA submissions for significant design modifications. Whether validating next generation framework designs or novel fabric configurations, our protocols address FDA expectations for LAA closure devices across intended patient populations.",Key Testing Capabilities,Nitinol Framework Performance,"Comprehensive framework testing quantifies expansion characteristics, wall apposition force distribution, and shape memory behavior across deployment conditions with fatigue protocols evaluating structural integrity throughout projected device lifetime.",Fabric Membrane Integration,"Specialized membrane assessment evaluates polyester fabric porosity, sealing effectiveness, and endothelialization support properties with testing protocols characterizing fabric-framework attachment integrity under physiological loading.",Device Sizing and Compression Ratio,Sizing algorithm validation across LAA diameters and depths ensures optimal device selection with compression ratio testing confirming adequate wall contact without excessive tissue compression across morphological variants.,Deployment Accuracy and Retrieval,"High-resolution imaging captures deployment dynamics, positioning precision, and device stability during cardiac motion with retrieval capability assessment validating recapture mechanics and redeployment performance.",Sealing Integrity and Leak Prevention,Advanced flow measurement techniques quantify complete LAA occlusion and peridevice leak detection with long-term sealing validation confirming permanent appendage isolation throughout extended observation periods.,Biocompatibility and Thrombogenicity,ISO 10993 compliant testing addresses nitinol and polyester fabric biocompatibility with specialized thrombogenicity protocols evaluating clot formation potential during anticoagulation bridging and long-term antithrombotic therapy.,Why Choose Synchrony for Watchman Device Testing,Microscope,Specialized LAA Closure Infrastructure,"Two catheterization laboratories configured specifically for Watchman device evaluation feature transesophageal echocardiography, high-resolution fluoroscopy, and specialized compression ratio testing equipment. Our anatomical model library includes all major LAA morphologies while nitinol characterization systems evaluate framework performance across temperature ranges and deployment scenarios encountered in clinical practice.",Users,Structural Heart Device Expertise,"Founded by Duke University interventional cardiologists who pioneered LAA closure procedures, our team understands Watchman device mechanics, sizing methodologies, and chronic tissue integration requirements. This cardiovascular specialization translates to protocol designs addressing nitinol framework validation, fabric membrane assessment, and the comprehensive safety testing FDA expects for percutaneous stroke prevention devices.",CheckCircle,Proven LAA Closure Regulatory Success,"Our data packages have supported successful FDA submissions for LAA closure devices across multiple platform generations. We understand Class III device requirements including nitinol biocompatibility demonstration, endothelialization validation, and the specific endpoints FDA expects for Watchman device submissions addressing stroke prevention in atrial fibrillation patients.",Ready to Start Your Study?,"Our team is ready to discuss your Watchman device, regulatory pathway, and study requirements to optimize your path to FDA approval.",Schedule Consultation,/contact
renal-denervation-testing,Renal Denervation Testing Services | GLP Preclinical CRO | Synchrony Labs,Structural Heart Testing,/preclinical-services/cardiovascular-disease-testing/structural-heart-testing,Renal Denervation Testing Services,"Specialized preclinical validation for catheter-based renal denervation systems with sympathetic nerve ablation assessment, energy delivery characterization, and chronic reinnervation evaluation.",What We Test,"Renal denervation devices treat resistant hypertension by disrupting sympathetic nerves surrounding renal arteries. These catheter-based systems must prove they can achieve complete nerve ablation while preserving renal artery integrity and kidney function. Whether using radiofrequency energy or ultrasound, devices need validation showing sustained blood pressure reduction without nerve regrowth over time.

We test nerve ablation effectiveness through specialized immunohistochemistry that visualizes sympathetic fiber destruction, measuring norepinephrine levels to confirm functional denervation, and tracking blood pressure changes that demonstrate therapeutic benefit. Our protocols evaluate energy delivery consistency across varying vessel anatomies, ensuring circumferential ablation without creating arterial injury. From acute safety assessment through extended reinnervation studies, our testing addresses the complete validation path these hypertension devices require.

ISO 10993 biocompatibility standards guide chronic arterial contact assessment while FDA guidance for neurological devices informs ablation validation protocols. Our testing supports both early feasibility studies under IDE applications and comprehensive PMA submissions. Whether validating radiofrequency catheter designs or ultrasound transducer arrays, our protocols demonstrate the ablation completeness and renal safety FDA expects for hypertension treatment devices.",Key Testing Capabilities,Sympathetic Nerve Ablation Verification,"Specialized immunohistochemistry visualizes sympathetic fiber destruction while norepinephrine analysis confirms functional denervation, with quantitative protocols characterizing ablation depth and completeness across arterial segments.",Energy Delivery Characterization,"Temperature and impedance monitoring track radiofrequency energy distribution and tissue contact quality while ultrasound mapping validates focal zones, penetration depth, and circumferential coverage achieving complete denervation.",Renal Artery Safety and Function Assessment,Angiography and intravascular ultrasound evaluate arterial integrity and healing while renal function monitoring confirms preserved kidney performance throughout chronic observation periods.,Chronic Reinnervation Evaluation,"Serial nerve fiber assessment at multiple timepoints detects sympathetic regrowth while blood pressure monitoring identifies therapeutic durability, with histological analysis characterizing long-term ablation stability.",Catheter Performance and Electrode Contact,Delivery system testing evaluates navigation through renal anatomy and electrode positioning while impedance monitoring confirms tissue contact and multi-electrode systems demonstrate circumferential ablation coverage.,Blood Pressure Response and Therapeutic Efficacy,Continuous hemodynamic monitoring tracks acute and chronic blood pressure changes with ambulatory assessment characterizing sustained response and protocols evaluating bilateral versus unilateral denervation effectiveness.,Why Choose Synchrony for Renal Denervation Testing,Target,Specialized Renal Denervation Infrastructure,"Two catheterization laboratories equipped for renal artery access feature specialized ablation monitoring systems and anatomical models spanning vessel size variations. Our nerve assessment capabilities include immunohistochemistry facilities, norepinephrine analysis equipment, and comprehensive blood pressure monitoring systems enabling complete denervation validation from acute ablation through chronic reinnervation assessment.",Users,Sympathetic Nerve Ablation Expertise,"Our team combines cardiovascular device experience with specialized knowledge of sympathetic nervous system anatomy and ablation technologies. This expertise translates to protocols addressing energy delivery optimization, nerve fiber assessment methodologies, and the chronic observation requirements hypertension devices demand for demonstrating sustained therapeutic benefit without sympathetic nerve regrowth.",Activity,Proven Ablation Device Regulatory Success,"Our data packages have supported FDA submissions for ablation-based therapeutic devices across multiple tissue targets. We understand neurological device guidance requirements, energy delivery safety validation, and the comprehensive efficacy demonstration FDA expects for devices treating systemic conditions through targeted nerve disruption addressing both acute ablation completeness and long-term therapeutic durability.",Ready to Start Your Study?,"Our team is ready to discuss your renal denervation device, regulatory pathway, and study requirements to optimize your path to FDA approval.",Schedule Consultation,/contact